Figure 5
Percentage inhibition of monocyte chemoattractant protein-1 (MCP-1) production (a) and nuclear factor-kappa B (NF-κB) activation (b) by the indicated concentrations of irbesartan (gray bar) and losartan (closed bar) in human coronary endothelial cells (HCECs). HCECs were grown in the absence or presence of the indicated concentrations of angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) under serum-free conditions for 24 h before the measurement of MCP-1 production and NF-κB activation. The percentage of basal MCP-1 production or NF-κB activation without ARB treatment under serum-free conditions for 24 h in HCECs was adjusted to 100%. *P<0.05 vs. no treatment. #P<0.05 vs. 1 μM losartan. Percent inhibition of MCP-1 production (c) and NF-κB activation (d) by 1 μM irbesartan and losartan in a Tet-ON system using HEK293 cells expressing the WT AT1 receptor. HEK293 cells were grown for 48 h using 0 (open bar), 100 (dotted bar) and 400 (stripe bar) mg ml−1 doxycycline for the induction of the WT AT1 receptor. After induction, HEK293 cells were grown in the absence or presence of irbesartan and losartan under serum-free conditions for 24 h before the measurement of MCP-1 production and NF-κB activation. The percentage of basal MCP-1 production or NF-kB activation without ARB treatment under serum-free conditions for 24 h in HEK293 cells was adjusted to 100%. *P<0.05 vs. no treatment. #P<0.05 vs. 1 μM losartan.
